Emyria Ltd · ASX:EMD
Emyria — ShareCafe Small Cap Hidden Gems Webinar 2024
29 slides from Emyria's conference presentation, Sep 6, 2024
Slide 1: Hidden Gems Webinar Presentation
Delivering & developing new treatments for mental health & neurological conditions ASX Announcement | 06 Sept 2024 Hidden Gems Webinar Presentation Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) delivering and developing new treatments for mental health and select neurological conditions, is
Slide 2: Emyria integrated model and cautionary note
emyria.com Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through through an integrated model of direct clinical services and drug development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from generates conventi
Slide 3: Hidden Gems Webinar: Delivering and developing new treatments for PTSD
For personal use only Hidden Gems Webinar Delivering and developing new treatments for PTSD ASX: EMD 06 September 2024
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. T
Slide 5: Corporate Details
EMYRIA (ASX: EMD) CORPORATE DETAILS SUBSTANTIAL SHAREHOLDERS For personal use only Shareholder % Tenmile 5.8% Top 20 56.3% ASX: EMD TRADING INFORMATION Share Price A$0.046 6-Month low / high A$0.032 / 0.07 Shares Outstanding 349,226,509 Market Capitalisation A$18.8M Cash (30 June 2024) A$1.9M* * Add
Slide 6: Mental health now Australia's #1 chronic health problem
Mental health now For personal use only Australia’s #1 chronic health problem Emyria 2024
Slide 7: Emyria's Mission
EMYRIA’S MISSION “ For personal use only To first transform PTSD care by developing and delivering new treatments that profoundly enhance patient well-being and quality of life. Emyria 2024
Slide 8: Tackling Post Traumatic Stress Disorder
TACKLING POST TRAUMATIC STRESS DISORDER A chronic, debilitating condition that can develop after experiencing, or repeatedly being exposed to, traumatic events For personal use only 7 % of adults 1 2 as common in x 1.5m Australians first responders 2 23m Americans $232 In Australia, workers B/yr comp
Slide 9: Current PTSD Treatment Approaches
CURRENT PTSD TREATMENT APPROACHES If patients can access the care they need, not all patients will respond For personal use only Biological Psychological Managed by specialists Managed by therapists Medications (Sertraline, Paroxetine) Therapies (CBT 2, Prolonged Exposure) Variable response, side ef
Slide 10: We Need a New Paradigm
WE NEED A NEW PARADIGM… Could we more deeply integrate the benefits of both approaches? For personal use only Biological Psychological Specialists Therapists Emyria 2024
Slide 11: MDMA-Assisted Therapy (MDMA-AT) for PTSD
MDMA-ASSISTED THERAPY (MDMA-AT) FOR PTSD 2-3 medication sessions with supportive therapy to enhance clinical response For personal use only MDMA-assisted therapy MDMA Supportive, trauma-informed (3,4-methylenedioxymeth- psychotherapy amphetamine or “ecstasy”) MDMA produces feelings of emotional conn
Slide 12: MDMA-AT for PTSD: Promising Outcomes in Phase 3 Trials
MDMA-AT FOR PTSD PROMISING OUTCOMES IN PHASE 3 TRIALS Key benefits after 3 DOSING SESSIONS For personal use only 86.5% of MDMA-AT participants reported improvement, compared to 69% in placebo group. MAPP2 71.2% of MDMA-AT participants no longer met PTSD criteria, compared to 47.6% in the placebo grou
Slide 13: MDMA-AT vs Gold Standard Care for PTSD
MDMA-AT vs GOLD STANDARD CARE FOR PTSD MDMA-AT showed high remission success and low dropout rates For personal use only References: L. Schoenmaker 2015, J. Schurr 2022, M. Schoefer 2019, S. Mitchell 2023, G. Mitchell 2023 SOURCES: 1. Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assi
Slide 14: Why Emyria has a remarkable opportunity
3 Reasons: For personal use only Why Emyria has such a remarkable opportunity to lead this important new approach to PTSD Commercial in confidence Emyria 2024 12
Slide 15: Australia's Unique Regulatory Environment
(1) AUSTRALIA’S UNIQUE REGULATORY ENVIRONMENT Australia has a significant, world-wide, first-mover advantage 1 July 2023 1 For personal use only TGA Legal access possible 9 August 2024 2 FDA ? 5 years SOURCES: 1. https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enabl
Slide 16: Emyria Has Solved the Complex Delivery Challenges
(2) EMYRIA HAS SOLVED THE COMPLEX DELIVERY CHALLENGES Skilled & trained 01 multi-disciplinary team (20+) For personal use only Team Secure supply of GMP-grade 02 Medicines medicines Evidence-based, 03 Protocols ethics-endorsed protocols A method for patients to fund 04 Funding treatment 05 Facilitie
Slide 17: A World-Class Facility
A WORLD-CLASS FACILITY Dedicated therapy rooms For personal use only Supported with technology to optimise evidence gathering and patient experience READY TO SCALE… Emyria 2024
Slide 18: Emyria's PTSD Program Is Delivering Patient Outcomes
(3) EMYRIA’S PTSD PROGRAM IS DELIVERING PATIENT OUTCOMES 60% average improvement in PTSD symptoms (as measured with the PCL-5 1) For personal use only All patients demonstrated a clinically - significant improvement in symptoms (change of 12 points of more) 2 50% of patients to remission (PCL-5 score
Slide 19: Emyria's PTSD Program Is Delivering Patient Outcomes (Quality of Life)
(3) EMYRIA’S PTSD PROGRAM IS DELIVERING PATIENT OUTCOMES 50% average improvement in Quality of Life (as measured with the ReQoL-5 1) For personal use only 75% of patients had a clinically - significant improvement in quality of life scores (> 10 point change) 2 Sources: 1. ReQoL: Recovering Quality o
Slide 20: Case Study: Kate (First Responder)
CASE STUDY | KATE (First Responder) ● Presented 2018 ● PTSD due to cumulative workplace traumas For personal use only ● Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare rescripting ● Different psychotropic medications ● Stuck, terrified
Slide 21: Case Study: Kate PCL-5 Trends Over Years
CASE STUDY | KATE | PCL-5 Trends Over 5 Years 2 years MDMA-AT commenced For personal use only 6m Emyria 2024
Slide 22: Creating global patient impact and long-term value
Creating global patient impact and For personal use only long-term value Commercial in confidence Emyria 2024 20
Slide 23: Creating Long-Term Value
CREATING LONG-TERM VALUE EXPAND CLINICAL DELIVER GLOBAL SERVICES PATIENT IMPACT For personal use only Workers Compensation Private Health Insurance Government Catalysts: Payer Engagement Short term Longer term Emyria 2024
Slide 24: Creating Long-Term Value
CREATING LONG-TERM VALUE EXPAND CLINICAL CREATE NEW DELIVER GLOBAL SERVICES TREATMENTS PATIENT IMPACT For personal use only Proprietary Data & Licensable Service IP Revenues Catalysts: Payer Engagement National Site & Service Expansion International Licensing & Partnerships Short term Longer term Em
Slide 25: Our Novel Drug Discovery Pipeline
OUR NOVEL DRUG DISCOVERY PIPELINE We have a large, patented library of MDMA-inspired candidates New Our leading development series: For personal use only medications Increase versatility of Help symptoms of EMD-MX1 drug-assisted therapy EMD-MX2 L-DOPA induced for mental health dyskinesia (LID), EMD-
Slide 26: Our World-Class Team
OUR WORLD-CLASS TEAM | CLINICS, DRUG APPROVALS, DATA For personal use only Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Non-Executive Managing Director Non-Executive Non-Executive Non-Executive Chairman Director Director Director ● Health Service ● Clinical Da
Slide 27: Key Milestones
KEY MILESTONES Next 6 months SERVICE Major hospital partnerships For personal use only DELIVERY Supported by Major payer engagement growing Launch 2nd psychedelic-assisted therapy program service revenues Expand Empax Centre locations DRUG ✓ Clear search report for MDMA analogue patent family DEVELO
Slide 28: Beyond PTSD
BEYOND PTSD Emyria’s model is poised to tackle additional unmet needs in mental health For personal use only Other major mental Major health Depressive challenges Disorder 12% of all adults 2 PTSD 7% of all adults 1 SOURCES: 1. https://www.phoenixaustralia.org/ptsd-awareness-day/ Emyria 2024 2. Bain
Slide 29: Contact Information
EMYRIA (ASX: EMD) CONTACT INFORMATION For personal use only Michael Winlo mwinlo@emyria.com Investors investors@emyria.com Media media@emyria.com General info@emyria.com https://investorhub.emyria.com/
Emyria — ShareCafe Small Cap Hidden Gems Webinar 2024 on 6ix